Login to view
Gregg Sherman, MD
Chief Medical Officer, NACE
Kilbride Associates Healthcare Communications
San Francisco, CA
Barbara Hutchinson, MD, PhD, FACC
President, Association of Black Cardiologists
President, Chesapeake Cardiac Care
Jan Basile, MD
Professor of Medicine
Seinsheimer Cardiovascular Health Program
Division of General Internal Medicine
Medical University of South Carolina
Ralph H. Johnson VA Medical Center
Mahfouz El Shahawy, MD, MS, FACP
Clinical Professor of Medicine
Universities of Florida and South Florida
Cardiovascular Health Assessment Center
President, Cardiovascular Center of Sarasota
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH
Professor of Medicine
Tulane University School of Medicine
Tulane Heart and Vascular Institute
New Orleans, LA
Robert L. Gillespie, MD, FACC, FASE, FASNC
Immediate Past Chairman of the Board, Association of Black Cardiologists
Director of Nuclear Imaging, Sharp Rees-Stealy Medical Group
San Diego, CA
New York, NY
Peter P. Toth, MD, PhD, FCCP, FAHA, FESC, FACC
Director of Preventative Cardiology
CGH Medical Center
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Karol E. Watson, MD, PhD
Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program Los Angeles, CA
Estimated Time To Complete CME Activity:
Welcome to the National Association for Continuing Education webcast from the NACE Emerging Challenges in Primary Care 2017 conference.
Dyslipidemia is a major risk factor for coronary heart disease. Low-density lipoprotein cholesterol (LDL-C) is a key lipid fraction that plays a causal role in atherosclerotic cardiovascular disease (ASCVD), and control of LDL-C levels can reduce the risk of coronary heart disease (CHD). In recent trials, the addition of a non-statin to dyslipidemia treatment resulted in incremental lowering of LDL-C levels and improved cardiovascular outcomes, thereby underlining the primacy of LDL-C lowering for reducing cardiovascular risk, and emphasizing that more intensive LDL-C reduction, is more effective than less intensive lipid management.
The monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) are new and exciting non-statin treatment options for dyslipidemia management. With the availability of these treatment options, there is a need for clinician education on the topic of dyslipidemia management, especially because it remains underdiagnosed and undertreated in practice.
This program will address the evidence behind primary and secondary prevention strategies for cardiovascular disease. The role and rationale for PCSK-9 inhibitors will be explored as well as current cardiovascular disease Quality Measures.
This webcast was recorded live and is being used with the permission of the presenters.
After completing this program participants should be able to:
- Employ evidence based treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations.
- Discuss ACC recommendations on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease.
- Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction.
- List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease.
How To Obtain Your CME Certificate 1. Register for the course at www.naceonline.com.
2. View the content.
3. Complete and submit the post-test and evaluation.
4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME
5. Print your CME certificate.
National Association for Continuing Education & Association of Black Cardiologists, Inc.
|Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education(which includes 0.75 pharmacology hours).
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.
Barbara Hutchinson, MD, PhD, FACC serves on the cardiovascular writing committee for ABIM.
Jan Basile, MD serves on the speakers bureau for Amgen, Arbor, and Janssen. Dr. Basile also serves as a consultant for Novartis, Medtronic, and Up-to-date.
Mahfouz El Shahawy, MD, MS, FACP has no relevant financial relationships to disclose.
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH serves as a consultant for Amgen, Novartis, Sanofi, and Quantum Genomics. Dr. Ferdinand also serves as a consultant/researcher for Boehringer-Ingelheim and as a researcher for Eli Lilly.
Robert L. Gillespie, MD, FACC, FASE, FASNC serves as the owner of Tricada.
Peter P. Toth, MD, PhD, FCCP, FAHA, FESC, FACC serves on the speakers bureau for Amgen, Amarin, Kowa, Merck, Regeneron, and Sanofi.
Karol E. Watson, MD, PhD serves as a consultant for Amarin and Amgen. Dr. Watson also serves as a consultant/speakers bureau member for Boehringer Ingleheim.
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Josh Kilbridge, Medical Writer, has no relationships to disclose.
Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
This educational activity is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.